In this episode of the Crux of Medtech Henry is joined by Thomas Looby, CEO of Conavi Medical.

Thomas breaks down why combining IVUS + OCT in a single catheter could change coronary interventions and how the team is pacing toward a Q3 2025 510(k) with a measured “crawl, walk, run” launch plan.

Expect candid insight on evidence, pricing, commercialisation, and strategic exit logic

Key Topics

The unmet need in PCI imaging and why single-modality tools leave blind spots.

Engineering IVUS + OCT into one catheter and testing lessons from v1 to next-gen.

Clinical evidence momentum: meta-analysis signals ~46% reduction in post-procedure mortality and ~52% less stent thrombosis.

Regulatory path: pre-sub complete; targeting a Q3 2025 510(k).

Commercial strategy: price-neutral entry, razor/razor-blade model, and a staged hospital rollout.

Capital story: public listing via Titan assets and a $20M raise led largely by U.S. investors.

Exit thinking: platform fit with strategics that currently have either IVUS or OCT Kanavi holds both.

Related Insights

Mission-driven teams as a magnet for top engineers and why it mattered here.

Don’t over-index on KOLs: early adopters forgive product “sins” that mainstream users won’t.

Market development should run in parallel with R&D, not after it.Canada-born tech, U.S.-centric commercialisation and how ecosystems and manufacturing partners align.

Core Challenges

Driving COGS down to single-modality parity at volume (supply chain, manufacturing).

Building broad market awareness beyond early KOL enthusiasm.

Navigating regulatory milestones cleanly to stay on a Q3 2025 filing cadence.

Competing with entrenched portfolios (Abbott, Philips, Boston) that bundle cath lab solutions.

Tune in now to learn how dual-modality imaging could reset outcomes, economics, and adoption in the cath lab.

The Crux of MedTech podcast is brought to you by Cruxx, a specialist surgical robotics recruitment agency.

To learn more about Cruxx,⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠click here.⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠

A big thank you to our sponsors on this season of the podcast;

⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠TTP plc⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ With a 35-year track record, TTP excels in turning innovative ideas into market-ready solutions. Their team of 300+ experts deliver breakthrough solutions in areas ranging from endoluminal robotics and navigation systems to ultrasound imaging. Whether you're a startup or a multinational, ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠TTP plc⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ can accelerate your development with the latest technologies. Learn more at ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠TTP.com⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠

&

⁠⁠⁠⁠⁠⁠⁠KUKA⁠⁠⁠⁠⁠⁠⁠ is a global leader in robotics with over 25 years of experience partnering with medtech companies on their journey to market. Their reputation is built on robust technology, reliability and long term collaboration and being more than just a supplier.

KUKA provides trusted support throughout the product life cycle, from development to integration and beyond. 

Find out more at ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠kuka.com/healthcare⁠⁠⁠

This episode of the Crux of Medtech features Sabine Bois, the former CEO of Occlutech.

Sabine is a medtech leader whose career spans founding startups, steering a company through bankruptcy, driving IPO prep, and ultimately leading as CEO.

Her story is raw, unfiltered, and filled with lessons about resilience, leadership, and navigating the brutal realities of medtech.

Key Topics:

• Sabine’s leap from small-town Germany to founding her first medtech startup

• Navigating bankruptcy and rebuilding into a successful acquisition

• The commercial lessons that reshaped her career trajectory

• Transition from CFO to CEO at Occlutech during global litigation and IPO prep

• The turbulence behind IPO readiness, audits, and roadshows

• Why passion and relentlessness matter more than resources
  

Related Insights:

• Failure wasn’t an option for the Wright brothers or for startups

• The CEO’s ability to adapt their pitch can make or break funding

• Timing and market cycles are often as critical as technology

• Strategics are approachable but require careful balance in what you share
  

Core Challenges:

• Surviving insolvency while protecting IP and technology

• Learning that a CEO’s first responsibility is revenue, not admin

• Facing last-minute IPO derailments and high-stakes investor negotiations

• Adjusting from European regulatory norms to the strict demands of the FDA

• Raising funds in today’s tougher, profitability-driven investor landscape

Tune in now to hear Sabine’s unfiltered journey through medtech’s toughest challenges and what it really takes to lead with resilience.

The Crux of MedTech podcast is brought to you by Cruxx, a specialist surgical robotics recruitment agency.

To learn more about Cruxx,⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠click here.⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠

A big thank you to our sponsors on this season of the podcast;

⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠TTP plc⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ With a 35-year track record, TTP excels in turning innovative ideas into market-ready solutions. Their team of 300+ experts deliver breakthrough solutions in areas ranging from endoluminal robotics and navigation systems to ultrasound imaging. Whether you're a startup or a multinational, ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠TTP plc⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ can accelerate your development with the latest technologies. Learn more at ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠TTP.com⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠

&

⁠⁠⁠⁠⁠⁠⁠KUKA⁠⁠⁠⁠⁠⁠⁠ is a global leader in robotics with over 25 years of experience partnering with medtech companies on their journey to market. Their reputation is built on robust technology, reliability and long term collaboration and being more than just a supplier.

KUKA provides trusted support throughout the product life cycle, from development to integration and beyond. 

Find out more at ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠kuka.com/healthcare⁠⁠⁠

In this episode, Henry Norton speaks with Adrian Mendes, CEO of Perimeter, a company using AI and optical imaging to tackle one of cancer surgery’s biggest problems: re operations

Adrian shares his journey from Silicon Valley tech to medtech, and unpacks how Perimeter is using real-time imaging and machine learning to give surgeons confidence they’ve removed all the cancer the first time.

They discuss the challenges of moving fast in healthcare, the value of proprietary data in AI, and how Perimeter is building for scale with a clear commercial and clinical roadmap.

Key Topics:

Why reoperations are such a huge problem in cancer care

How OCT and AI work together during surgery

The culture problem slowing down medtech innovation

What sets “real” AI apart from buzzword AI

Commercial rollout plans and how they’re scaling

The long-term vision to expand beyond breast cancer

Related Insights:

“Clear margins” are one of the biggest unmet needs in cancer surgery

AI in healthcare is only useful if it's usable surgeon workflow matters

Proprietary data is more defensible than algorithms alone

Core Challenges:

Healthcare’s cautious culture often slows meaningful innovation

Many “AI” medtech products are just marketing

Commercial scale is hard when you’re building from a startup base

🎧 Tune in now to hear how Perimeter is building medtech that actually makes surgery smarter.

The Crux of MedTech podcast is brought to you by Cruxx, a specialist surgical robotics recruitment agency.

To learn more about Cruxx,⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠click here.⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠

A big thank you to our sponsors on this season of the podcast;

⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠TTP plc⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ With a 35-year track record, TTP excels in turning innovative ideas into market-ready solutions. Their team of 300+ experts deliver breakthrough solutions in areas ranging from endoluminal robotics and navigation systems to ultrasound imaging. Whether you're a startup or a multinational, ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠TTP plc⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ can accelerate your development with the latest technologies. Learn more at ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠TTP.com⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠

&

⁠⁠⁠⁠⁠⁠KUKA⁠⁠⁠⁠⁠⁠ is a global leader in robotics with over 25 years of experience partnering with medtech companies on their journey to market. Their reputation is built on robust technology, reliability and long term collaboration and being more than just a supplier.

KUKA provides trusted support throughout the product life cycle, from development to integration and beyond. 

Find out more at ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠kuka.com/healthcare⁠⁠⁠

Why are so few patients accessing the care they need when the tech is already here? In this episode, Henry Norton sits down with David Pettigrew CEO at my mhealth to unpack the real reasons digital health tools succeed or fail.

From overlooked rehabilitation gaps to the power of patient-first design, this conversation spotlights how we can actually get medtech into the hands of the people who need it most.

David shares his career pivot from corporate dream job to healthtech entrepreneur, and what it’s really like building products that serve thousands of patients. You’ll hear why uptake often has nothing to do with clinical data… and everything to do with how a product makes someone feel.

Key Topics

• Why David left a “dream job” for a mission-driven startup

• How digital health tools can close the rehab gap

• What makes an app truly “sticky” for users

• The business model tensions slowing down innovation

• Lessons from working directly with patients, not just clinicians

  
  

  Related Insights

• Simplicity drives adoption more than clinical complexity

• Patient awareness is often the biggest bottleneck
• Scaling isn’t just about funding — it’s about access and trust

Core Challenges

• Only 3% of patients in the U.S. get the rehab they need

• Traditional care pathways don’t scale to meet demand
• Many digital tools fail due to poor design and awareness

The Crux of MedTech podcast is brought to you by Cruxx, a specialist surgical robotics recruitment agency.

To learn more about Cruxx,⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠click here.⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠

A big thank you to our sponsors on this season of the podcast;

⁠⁠⁠⁠⁠⁠⁠⁠⁠TTP plc⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ With a 35-year track record, TTP excels in turning innovative ideas into market-ready solutions. Their team of 300+ experts deliver breakthrough solutions in areas ranging from endoluminal robotics and navigation systems to ultrasound imaging. Whether you're a startup or a multinational, ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠TTP plc⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ can accelerate your development with the latest technologies. Learn more at ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠TTP.com⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠

&

⁠⁠⁠⁠⁠KUKA⁠⁠⁠⁠⁠ is a global leader in robotics with over 25 years of experience partnering with medtech companies on their journey to market. Their reputation is built on robust technology, reliability and long term collaboration and being more than just a supplier.

KUKA provides trusted support throughout the product life cycle, from development to integration and beyond. 

Find out more at ⁠⁠⁠⁠⁠⁠⁠⁠⁠kuka.com/healthcare⁠⁠

In this episode, your host, Henry Norton, is joined by Hannah Claridge, the Head of Neurotechnology at TTP, to talk about the incredible advancements that are being made to treat neurological conditions. 

Hannah points out how complex the brain and nervous systems are, with both relying on intricate connections. She also explores the new technologies that are being developed to treat nervous disorders, such as spinal cord stimulation. 

She also compared neurotechnologies to pharmaceuticals, highlighting the parallels and differences in how they interact with the body. 

Hannah also suggested that neurotherapy will be key to the advancement of treatments for conditions like depression, due to their ability to provide targeted and long-term relief of symptoms. 

Cybersecurity is also a major concern for neurotechnology, as any malfunction or deliberate interference could have serious ramifications for patients. 

Key Topics: 

• Hannah’s current role at TTP 

• Recent innovations in neurotechnology 

• Policy and ethics in neurotech

• Barriers to market adoption 

• Moving patient stories 

Related Insights: 

• Humans use far more than 10% of the brain - this was debunked during a conversation about brain plasticity 

• There are significant barriers to market adoption for neurosurgery, such as a lack of awareness and understanding, even among surgeons. 

• Neurotech’s impact on patients cannot be understated, as so many conditions are currently untreatable with other intervention methods. 

Core Challenges:

• Anything that interacts with the brain in a way that changes its fundamental functions comes with huge ethical concerns and a need for heightened patient understanding and clear consent. 

• Neurotechnology can provide relief for chronic conditions, such as long-term pain relief and the alleviation of depressive symptoms, making it a game-changing device in several areas. 

• The challenges when it comes to developing a new neurotech product from being intuitive to miniaturisation.

Tune in now to find out how neurotechnology will change healthcare for the better. 

The Crux of MedTech podcast is brought to you by Cruxx, a specialist surgical robotics recruitment agency.

To learn more about Cruxx,⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠click here.⁠⁠⁠⁠⁠⁠⁠⁠⁠

A big thank you to our sponsors on this season of the podcast;

⁠⁠⁠⁠⁠⁠⁠⁠TTP plc⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ With a 35-year track record, TTP excels in turning innovative ideas into market-ready solutions. Their team of 300+ experts deliver breakthrough solutions in areas ranging from endoluminal robotics and navigation systems to ultrasound imaging. Whether you're a startup or a multinational, ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠TTP plc⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ can accelerate your development with the latest technologies. Learn more at ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠TTP.com⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠

&

⁠⁠⁠⁠KUKA⁠⁠⁠⁠ is a global leader in robotics with over 25 years of experience partnering with medtech companies on their journey to market. Their reputation is built on robust technology, reliability and long term collaboration and being more than just a supplier.

KUKA provides trusted support throughout the product life cycle, from development to integration and beyond. 

Find out more at ⁠⁠⁠⁠⁠⁠⁠⁠kuka.com/healthcare⁠

Raising capital in Medtech is tougher than ever. Investor expectations have shifted. Competition is up. And many founders are still pitching like it’s 2018.

In this episode, Henry Norton sits down with Kiko Filipov, Partner at APPARIUS Corporate Finance and Strategic Advisor at Cruxx, to unpack the real mechanics of a successful fundraise in 2025. From first-in-human data to commercial readiness, Kiko shares what separates the rounds that get oversubscribed from the ones that stall.

He also explores the changing landscape of Medtech innovation and why strategic exits take years of planning, how emerging markets are joining the race, and where VCs are placing bets across surgical robotics, neurostimulation, and digital health.

Whether you're gearing up for Series A or preparing your pitch deck, this episode delivers tactical clarity from someone who’s in the room with both founders and funds.

Key Topics:

What VCs actually look for in a Medtech pitch

Building an equity story that sells

Why surgical robotics and neurostimulation are hot right now

The key traits of an acquirable company

Common reasons fundraises fall flat

Related Insights:

Strategic hires matter just as much as the product

Market conditions now demand clearer commercial pathways

Software alone isn't enough, hybrid models are rising

Investors are more risk-averse and selective than ever

Core Challenges:

More competition than ever for VC attention

Delayed investment timing across the board

Burnout risk from unstructured fundraising efforts

Difficulties scaling across fragmented EU markets

🎧 Tune in now to learn what it really takes to raise and exit in Medtech.

The Crux of MedTech podcast is brought to you by Cruxx, a specialist surgical robotics recruitment agency.

To learn more about Cruxx,⁠⁠⁠⁠⁠⁠⁠⁠ ⁠click here.⁠⁠⁠⁠⁠⁠⁠⁠

A big thank you to our sponsors on this season of the podcast;

⁠⁠⁠⁠⁠⁠⁠TTP plc⁠⁠⁠⁠⁠⁠⁠⁠⁠ With a 35-year track record, TTP excels in turning innovative ideas into market-ready solutions. Their team of 300+ experts deliver breakthrough solutions in areas ranging from endoluminal robotics and navigation systems to ultrasound imaging. Whether you're a startup or a multinational, ⁠⁠⁠⁠⁠⁠⁠⁠⁠TTP plc⁠⁠⁠⁠⁠⁠⁠⁠⁠ can accelerate your development with the latest technologies. Learn more at ⁠⁠⁠⁠⁠⁠⁠⁠⁠TTP.com⁠⁠⁠⁠⁠⁠⁠⁠⁠

&

⁠⁠⁠KUKA⁠⁠⁠ is a global leader in robotics with over 25 years of experience partnering with medtech companies on their journey to market. Their reputation is built on robust technology, reliability and long term collaboration and being more than just a supplier.

KUKA provides trusted support throughout the product life cycle, from development to integration and beyond. 

Find out more at ⁠⁠⁠⁠⁠⁠⁠kuka.com/healthcare

Join host Henry Norton in this episode of The Crux of Medtech as he speaks to Paul Roberts, co-founder of CMR Surgical and current CEO of Lupin Dental.

Paul shares the journey from building surgical robots in a former pig shed to co-founding one of the most recognised names in robotic surgery. Now, he’s applying that experience to an entirely new frontier, aesthetic dental robotics.

In this episode, Paul explains why dental veneers are about more than vanity, how robotic precision can eliminate outdated practices like tooth stumping, and why Lupin’s tech could completely transform smile restoration.

He also opens up about his medtech philosophy, including why engineers shouldn’t build products alone, and what it really takes to move from zero to launch in a capital-intensive field like robotics.

Key Topics

Why Paul left surgical robotics for dental robotics

The founding story of CMR Surgical

The clinical and aesthetic importance of veneers

How Lupin reduces a 5-visit dental process into 1

What medtech can learn from AlignTech and Invisalign

Building a profitable robot company without hundreds of millions

Related Insights

Crowns are outdated. Robotic veneers restore enamel with less damage

Engineers alone don’t make great products clinicians must co-create

One robotic session at Lupin replaces five traditional dental visits

India is a strategic first market and a smart regulatory play

Fail fast, but never compromise on patient safety

Core Challenges

Tooth restoration has long been inefficient: dentists rely on hand-guesswork for shaping and prepping teeth. It’s a manual, error-prone process that requires multiple appointments and can cause long-term sensitivity.

Lupin Dental solves this with AI-powered planning, CAD design, and a precision robot that prepares the tooth and bonds the veneer all in one session.

Tune in now to hear how surgical-grade robotics are reshaping the smile economy and why Lupin Dental could be the next CMR.

*The Lupin® Robotic System is not currently approved for clinical use in USA or EU.

The Crux of MedTech podcast is brought to you by Cruxx, a specialist surgical robotics recruitment agency.

To learn more about Cruxx,⁠⁠⁠⁠⁠⁠⁠ ⁠click here.⁠⁠⁠⁠⁠⁠⁠

A big thank you to our sponsors on this season of the podcast;

⁠⁠⁠⁠⁠⁠TTP plc⁠⁠⁠⁠⁠⁠⁠⁠ With a 35-year track record, TTP excels in turning innovative ideas into market-ready solutions. Their team of 300+ experts deliver breakthrough solutions in areas ranging from endoluminal robotics and navigation systems to ultrasound imaging. Whether you're a startup or a multinational, ⁠⁠⁠⁠⁠⁠⁠⁠TTP plc⁠⁠⁠⁠⁠⁠⁠⁠ can accelerate your development with the latest technologies. Learn more at ⁠⁠⁠⁠⁠⁠⁠⁠TTP.com⁠⁠⁠⁠⁠⁠⁠⁠

&

⁠⁠KUKA⁠⁠ is a global leader in robotics with over 25 years of experience partnering with medtech companies on their journey to market. Their reputation is built on robust technology, reliability and long term collaboration and being more than just a supplier.

KUKA provides trusted support throughout the product life cycle, from development to integration and beyond. 

Find out more at ⁠⁠⁠⁠⁠⁠kuka.com/healthcare

Meet Peter Verrillo, the CEO of Redefine Surgery. He joins your host, Henry Norton, in this episode to discuss the latest developments in orthopaedic AI. 

Throughout the conversation, Peter highlights how time-consuming knee surgery can be, and talks about the AI solutions that his company is creating to reduce the time spent in theatre. 

Peter also shares his journey as a founder of multiple different companies, touching on everything from funding and acquisitions to building prototypes in his basement. 

He also emphasises the benefits of working with device-manufacturing companies, as they will take his AI to market under a whitelabel. He states that this relationship is a key part of the medtech industry. 

Peter also touches on the importance of strong sales reps, suggesting that they should have training in both the software and robotics sides of this new technology in order to efficiently translate it to surgeons. 

Key Topics: 

• Peter’s journey from Stryker to founding his own companies

• The benefits of AI-assisted surgical technology 

• The entrepreneurial spirit 

• Redefine Surgery’s vision for the future of orthopaedic procedures

• Finding the right people for a medtech team 

Related Insights: 

• Fully understanding your patient’s problem before incision is key to a quick surgery

• AI isn’t a mystical system anymore - it’s a key part of the future of surgery 

• Creating your own team from scratch can be easier than slotting into an existing group 

Core Challenges:

• Knee surgery often takes 45 minutes per person due to the need for readjustments once surgeons can see inside the joint. 

• With AI-assisted technology, the time to operate can be brought down to as little as ten minutes thanks to preoperative assessments. 

Tune in now to find out how orthopaedic surgery will change in the coming years. 

The Crux of MedTech podcast is brought to you by Cruxx, a specialist surgical robotics recruitment agency.

To learn more about Cruxx,⁠⁠⁠⁠⁠⁠⁠ ⁠click here.⁠⁠⁠⁠⁠⁠⁠

A big thank you to our sponsors on this season of the podcast;

⁠⁠⁠⁠⁠⁠TTP plc⁠⁠⁠⁠⁠⁠⁠⁠ With a 35-year track record, TTP excels in turning innovative ideas into market-ready solutions. Their team of 300+ experts deliver breakthrough solutions in areas ranging from endoluminal robotics and navigation systems to ultrasound imaging. Whether you're a startup or a multinational, ⁠⁠⁠⁠⁠⁠⁠⁠TTP plc⁠⁠⁠⁠⁠⁠⁠⁠ can accelerate your development with the latest technologies. Learn more at ⁠⁠⁠⁠⁠⁠⁠⁠TTP.com⁠⁠⁠⁠⁠⁠⁠⁠

&

⁠⁠KUKA⁠⁠ is a global leader in robotics with over 25 years of experience partnering with medtech companies on their journey to market. Their reputation is built on robust technology, reliability and long term collaboration and being more than just a supplier.

KUKA provides trusted support throughout the product life cycle, from development to integration and beyond. 

Find out more at ⁠⁠⁠⁠⁠⁠kuka.com/healthcare

Join your host, Henry Norton, and David Caumartin, the CEO of RebrAIn, as they discuss the impact that machine learning and artificial intelligence are having on the clinical outcomes of neurosurgery procedures. 

During the episode, David shares his medtech story, from how he entered the field to what drew him to RebrAIn several years ago. 

He also talks about his experience of working with neurosurgeons and how that differs from the other fields he specialised in, such as mammography. 

David goes on to discuss the benefits of AI in the surgical space, suggesting that it can improve surgeons’ accuracy, patient outcomes and medical research. 

He also touched on RebrAIn’s clinical trials and the findings that are emerging from them. 

Key Topics: 

• David’s transition from GE to startup

• RebrAIn’s unique AI technology 

• The challenges and opportunities within the US market

• The impact of AI on healthcare

Related Insights: 

• AI is making healthcare smarter, faster, and more efficient 

• Collaboration is the key to progress in the healthcare field 

• RebrAIn’s technology can create accurate targets from 100 cases rather than 20,000

Core Challenges:

• The brain is one of the most delicate parts of human anatomy. In order to successfully operate on it, surgeons have to be as precise as possible. Factors like hand tremors, indecision or human error can have a huge impact on patient outcomes.  

• With an AI assistant, surgeons can assess the best course of action more quickly and accurately. RebrAIn’s AI tool serves as another neurosurgeon in the room. 

Tune in now to discover the future of neurosurgery.

The Crux of MedTech podcast is brought to you by Cruxx, a specialist surgical robotics recruitment agency.

To learn more about Cruxx,⁠⁠⁠⁠⁠⁠ ⁠click here.⁠⁠⁠⁠⁠⁠

A big thank you to our sponsors on this season of the podcast;

⁠⁠⁠⁠⁠TTP plc⁠⁠⁠⁠⁠⁠⁠ With a 35-year track record, TTP excels in turning innovative ideas into market-ready solutions. Their team of 300+ experts deliver breakthrough solutions in areas ranging from endoluminal robotics and navigation systems to ultrasound imaging. Whether you're a startup or a multinational, ⁠⁠⁠⁠⁠⁠⁠TTP plc⁠⁠⁠⁠⁠⁠⁠ can accelerate your development with the latest technologies. Learn more at ⁠⁠⁠⁠⁠⁠⁠TTP.com⁠⁠⁠⁠⁠⁠⁠

&

⁠KUKA⁠ is a global leader in robotics with over 25 years of experience partnering with medtech companies on their journey to market. Their reputation is built on robust technology, reliability and long term collaboration and being more than just a supplier.

KUKA provides trusted support throughout the product life cycle, from development to integration and beyond. 

Find out more at ⁠⁠⁠⁠⁠kuka.com/healthcare

In this episode, your host, Henry Norton, is joined by Dimitri Sokolov, the CEO at Spiro Robotics, to talk about the limitations of laryngoscopy tools, and what Spiro is doing to remove them. 

Dimitri explained the difficulties with current intubation methods, as well as the dangers of unsuccessful procedures. 

He went on to discuss the challenges of getting FDA approval for a new piece of medical robotics. 

Dimitri also shared some of the adjustments he’s had to make as he moved into the role of CEO, particularly in a small company. This includes growing a team and equipping them to perform at their full capacity. 

He also shared his story of getting into medical engineering. 

Key Topics: 

• Dimitri’s path to joining Spiro Robotics 

• The challenges of tracheal intubation 

• Precision-based solutions to medical interventions 

• How robotics can solve staffing shortages 

Related Insights: 

• The trials of clinical submissions 

• The value of clinical studies and partnerships 

• The opportunities for global advancements 

Core Challenges:

• Tracheal intubation is currently difficult for a lot of reasons, and often leads to cancelled surgeries in more troublesome cases. This is an issue for patients, surgeons, and anesthesiologists.  

• Spiro Robotics have created an intubation solution that enables quicker and more precise procedures, while also removing the need for a second physician in the room. 

Listen in to this episode to find out more about intubating safely and effectively. 

The Crux of MedTech podcast is brought to you by Cruxx, a specialist surgical robotics recruitment agency.

To learn more about Cruxx,⁠⁠⁠⁠⁠ ⁠click here.⁠⁠⁠⁠⁠

A big thank you to our sponsors on this season of the podcast;

⁠⁠⁠⁠TTP plc⁠⁠⁠⁠⁠⁠ With a 35-year track record, TTP excels in turning innovative ideas into market-ready solutions. Their team of 300+ experts deliver breakthrough solutions in areas ranging from endoluminal robotics and navigation systems to ultrasound imaging. Whether you're a startup or a multinational, ⁠⁠⁠⁠⁠⁠TTP plc⁠⁠⁠⁠⁠⁠ can accelerate your development with the latest technologies. Learn more at ⁠⁠⁠⁠⁠⁠TTP.com⁠⁠⁠⁠⁠⁠

&

⁠KUKA⁠⁠ is a global leader in robotics with over 25 years of experience partnering with medtech companies on their journey to market. Their reputation is built on robust technology, reliability and long term collaboration and being more than just a supplier.

KUKA provides trusted support throughout the product life cycle, from development to integration and beyond. 

Find out more at ⁠⁠⁠⁠⁠⁠kuka.com/healthcare